N-[2-[[[4-[[(acetyloxy)imino](amino)methyl]phenyl]methyl][3-(1-pyrrolidinyl)propyl]amino]-2-oxoethyl]-2-[[(2,4-dichloro-3-methylphenyl)sulphonyl](2-phenylethyl)amino]acetamide | 441293-43-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[2-[[[4-[[(acetyloxy)imino](amino)methyl]phenyl]methyl][3-(1-pyrrolidinyl)propyl]amino]-2-oxoethyl]-2-[[(2,4-dichloro-3-methylphenyl)sulphonyl](2-phenylethyl)amino]acetamide
• 英文别名: [[Amino-[4-[[[2-[[2-[(2,4-dichloro-3-methylphenyl)sulfonyl-(2-phenylethyl)amino]acetyl]amino]acetyl]-(3-pyrrolidin-1-ylpropyl)amino]methyl]phenyl]methylidene]amino] acetate
• CAS: 441293-43-2
• 化学式: C₃₆H₄₄Cl₂N₆O₆S
• 分子量: 759.754
• InChiKey: OZLXEKQDJQKBQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  51
• 可旋转键数：
  18
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  163
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use
  申请人：——

  公开号：US20040063725A1

  公开（公告）日：2004-04-01

  The present invention relates to novel N-(phenylsulphonyl)glycyl-glycine compounds, which are defined by formula I and the description, as well as their method of preparation and their use in therapeutics 1

  本发明涉及一种新颖的N-(苯磺酰基)甘氨酰甘氨酸化合物，其由式I和描述所定义，以及它们的制备方法及在治疗中的用途。
• Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates
  申请人：——

  公开号：US20040077664A1

  公开（公告）日：2004-04-22

  Pharmaceutical preparation comprising at least one phosphodiesterase V inhibitor and at least one nitrate for the preparation of a medicament for the treatment of angina, high blood pressure, pulmonary hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale, dextrocardiac insufficiency, atherosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, strokes, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, renal insufficiency and liver cirrhosis.

  含有至少一种磷酸二酯酶V抑制剂和至少一种硝酸盐的药物制剂，用于制备治疗心绞痛、高血压、肺动脉高压、充血性心力衰竭（CHF）、慢性阻塞性肺疾病（COPD）、肺心病、右心衰竭、动脉粥样硬化、心血管通路通畅度降低、外周血管疾病、中风、支气管炎、过敏性哮喘、慢性哮喘、过敏性鼻炎、青光眼、肠易激综合征、肿瘤、肾功能不全和肝硬化的药物。
• Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists
  申请人：——

  公开号：US20040063731A1

  公开（公告）日：2004-04-01

  Pharmaceutical preparation comprising at least one phosphodiesterase V inhibitor have, and/or physiologically acceptable salts and/or solvates thereof and at least one endothelin receptor antagonist for the preparation of a medicament for the treatment of angina, high blood pressure, high pulmonary pressure, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale, dextrocardiac insufficiency, atherosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, strokes, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, renal insufficiency, liver cirrhosis, erectile dysfunction and for the treatment of female sexual disorders.

  含有至少一种磷酸二酯酶V抑制剂，和/或其生理上可接受的盐和/或溶剂，以及至少一种内皮素受体拮抗剂的制药制剂，用于制备治疗心绞痛、高血压、高肺动脉压、充血性心力衰竭（CHF）、慢性阻塞性肺疾病（COPD）、肺心病、右心衰竭、动脉粥样硬化、心血管疾病血管通透性降低、周围血管疾病、中风、支气管炎、过敏性哮喘、慢性哮喘、过敏性鼻炎、青光眼、肠易激综合征、肿瘤、肾功能不全、肝硬化、勃起功能障碍和治疗女性性功能障碍的药物。
• PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
  申请人：MERCK PATENT GmbH

  公开号：EP1357915A2

  公开（公告）日：2003-11-05
• [EN] PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS<br/>[FR] PREPARATION PHARMACEUTIQUE COMPRENANT DES PYRAZOLO[4,3-D]PYRIMIDINES ET DES ANTAGONISTES DU RECEPTEUR DE L'ENDOTHELINE OU DES THIENOPYRIMIDINES ET DES ANTAGONSITES DU RECEPTEUR DE L'ENDOTHELINE
  申请人：MERCK PATENT GMBH

  公开号：WO2002062343A2

  公开（公告）日：2002-08-15

  Pharmaceutical preparation comprising at least one phosphodiesterase V inhibitor have, and/or physiologically acceptable salts and/or solvates thereof and at least one endothelin receptor antagonist for the preparation of a medicament for the treatment of angina, high blood pressure, high pulmonary pressure, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale, dextrocardiac insufficiency, atherosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, strokes, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, renal insufficiency, liver cirrhosis, erectile dysfunction and for the treatment of female sexual disorders.